minoxidil has been researched along with Hyperandrogenism in 4 studies
Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia." | 9.10 | Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. ( Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002) |
| "To compare topical minoxidil 2% and cyproterone acetate in the treatment of female alopecia." | 5.10 | Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. ( Boudou, P; Chaspoux, C; Fiet, J; Hardy, N; Jouanique, C; Reygagne, P; Vexiau, P, 2002) |
| "Female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women." | 2.66 | Female Androgenetic Alopecia: An Update on Diagnosis and Management. ( Alessandrini, A; Orlando, G; Piraccini, BM; Starace, M, 2020) |
| "(i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia." | 2.61 | Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ( Azziz, R; Bergfeld, W; Carmina, E; Escobar-Morreale, HF; Futterweit, W; Huddleston, H; Lobo, R; Olsen, E, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Starace, M | 1 |
| Orlando, G | 1 |
| Alessandrini, A | 2 |
| Piraccini, BM | 2 |
| Carmina, E | 1 |
| Azziz, R | 1 |
| Bergfeld, W | 1 |
| Escobar-Morreale, HF | 1 |
| Futterweit, W | 1 |
| Huddleston, H | 1 |
| Lobo, R | 1 |
| Olsen, E | 1 |
| Vexiau, P | 1 |
| Chaspoux, C | 1 |
| Boudou, P | 1 |
| Fiet, J | 1 |
| Jouanique, C | 1 |
| Hardy, N | 1 |
| Reygagne, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Botulinum Toxin in the Treatment of Androgenic Alopecia[NCT05456087] | Phase 2 | 20 participants (Anticipated) | Interventional | 2022-08-12 | Recruiting | ||
| International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia[NCT05888922] | Phase 3 | 520 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for minoxidil and Hyperandrogenism
| Article | Year |
|---|---|
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Androgenetic Alopecia: An Update on Diagnosis and Management.
Topics: Alopecia; Androgen Antagonists; Disease Progression; Female; Hair; Humans; Hyperandrogenism; Minoxid | 2020 |
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Humans; Hyperandrogenism; Low- | 2019 |
Androgenetic alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Biopsy; Comorbidity; Contraindications | 2014 |
1 trial available for minoxidil and Hyperandrogenism
| Article | Year |
|---|---|
Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial.
Topics: Administration, Topical; Adult; Alopecia; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2002 |